Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis

Guru Subramanian Guru Murthy, MD, Soyoung Kim, Zhen-Huan Hu, MPH, Noel Estrada-Merly, MS, Ryotaro Nakamura, MD, Betul Oran, MDMS, Bart L. Scott, MD, Ronald Sobecks, MD, Wael Saber, MD MS

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-140647

Published: 2020

Journal Articles

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Marcelo C. Pasquini, MDMS, Frederick L. Locke, MD, Alex F. Herrera, MD, Tanya Siddiqi, MD, Armin Ghobadi, MD, Krishna V Komanduri, MD, Zhen-Huan Hu, MPH, Hua Dong, PhD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Anna Purdum, PharmD,MS, Mary M. Horowitz, Michelle Hooper, Jun Kawashima, MD, Caron A. Jacobson, MD

Blood (2019) 134 (Supplement_1): 764.

https://doi.org/10.1182/blood-2019-124750

Published: 2019

Journal Articles

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Samantha Jaglowski, MD, Zhen-Huan Hu, MPH, Yiyun Zhang, PhD, Manali Kamdar, MD, Monalisa Ghosh, Premal Lulla, MBBS, Joshua Sasine, MD PhD, Miguel-Angel Perales, MD, Peiman Hematti, MD, Sarah Nikiforow, MD PhD, Patricia Steinert, PhD, Margit Jeschke, PhD, Lan Yi, PhD, Raghav Chawla, MD PhD, Lida Pacaud, Mary M. Horowitz, Eric Bleickardt, MD, Marcelo C. Pasquini, MDMS

Blood (2019) 134 (Supplement_1): 766.

https://doi.org/10.1182/blood-2019-130983

Published: 2019

Journal Articles

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry

Blood (2019) 134 (Supplement_1): 2619.

https://doi.org/10.1182/blood-2019-129279

Published: 2019

Journal Articles

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee

Aziz Nazha, Zhen-Huan Hu, MPH, Tao Wang, PhD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, R. Coleman Lindsley, MD, PhD, Ronald Sobecks, MD, Uday Popat, MD, Bart L Scott, MD, Wael Saber, MD MS

Blood (2018) 132 (Supplement 1): 206.

https://doi.org/10.1182/blood-2018-99-118677

Published: 2018

Journal Articles

Tyrosine Kinase Inhibitors with or without Donor Lymphocyte Infusion Continue to Provide Long-Term Survival after Relapse of Chronic Myeloid Leukemia Following Hematopoietic Cell Transplantation

Sarah Ann Schmidt, PharmD, Jennifer Holter Chakrabarty, MD, Ying Liu, PhD, Zhen-Huan Hu, MPH, Kirsten M. Williams, MD, Edwin P. Alyea, III, MD, Uday Popat, MD, Ronald Sobecks, MD, Bart L Scott, MD, Wael Saber, MD MS

Blood (2018) 132 (Supplement 1): 704.

https://doi.org/10.1182/blood-2018-99-118918

Published: 2018

Journal Articles

Telomere Length and Telomerase Complex Mutations Predict Fatal Treatment Toxicity after Stem Cell Transplantation in Patients with Myelodysplastic Syndrome

Mikko Myllymaki, MD PhD, Robert A. Redd, MS, Corey S. Cutler, MD MPH, Wael Saber, MD MS, Zhen-Huan Hu, MPH, Tao Wang, PhD, Stephen R. Spellman, Christopher J. Gibson, MD, Maxine M Chen, Esther Orr, David P. Steensma, MD, Joseph H. Antin, MD, Immaculata De Vivo, Donna S Neuberg, ScD, Suneet Agarwal, MDPhD, R. Coleman Lindsley, MD, PhD

Blood (2018) 132 (Supplement 1): 796.

https://doi.org/10.1182/blood-2018-99-117031

Published: 2018

Journal Articles

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Blood (2018) 132 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2018-99-119002

Published: 2018

Journal Articles

Comparison of Outcomes after Myeloablative Versus Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia

Saurabh Chhabra, MD, Kwang Woo Ahn, PhD, Zhen-Huan Hu, MPH, Sandeep Jain, MBBS, MRCP, Robert K. Stuart, MD, Matt Kalaycio, MD, Uday Popat, MD, Ronald Sobecks, MD, Edwin Alyea, III, MD, Wael Saber, MD MS

Blood (2017) 130 (Supplement 1): 600.

https://doi.org/10.1182/blood.V130.Suppl_1.600.600

Published: 2017

Journal Articles

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocyteic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneit HCT: A CIBMTR Report

Haesook T Kim, PhD, Zhen-Huan Hu, MPH, Kwang Woo Ahn, PhD, Matthew Davids, MD, Virginia Volpe, MD, Edwin Alyea, MD, Uday Popat, MD, Ronald Sobecks, MD, Wael Saber, MD MS, Jennifer Brownn, MD PhD

Blood (2017) 130 (Supplement 1): 667.

https://doi.org/10.1182/blood.V130.Suppl_1.667.667

Published: 2017

Journal Articles

Optimal Timing of Allogeneic Stem Cell Transplantation (Allo-SCT) for Chronic Myeloid Leukemia (CML) Patients in the Tyrosine Kinase Inhibitor (TKI) Era

Bei Hu, Xiao Lin, ^, Hans C. Lee, MD, Xuelin Huang, PhD, Rebecca Slack, MS, Elias J. Jabbour, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MBBS, Guillermo Garcia-Manero, MD, Richard E Champlin, MD, Zhen-Huan Hu, MPH, Kwang Woo Ahn, PhD, Ying Lee, MD, Uday Popat, MD, Ronald Sobecks, MD, Edwin Alyea, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Wael Saber, MD MS

Blood (2017) 130 (Supplement 1): 4582.

https://doi.org/10.1182/blood.V130.Suppl_1.4582.4582

Published: 2017

Journal Articles

Assessment of Human Leukocyte Antigen (HLA) Type on Outcomes of Allogeneic Transplant for Chronic Lymphocytic Leukemia (CLL)

Brian T. Hill, MD PhD, Kwang Woo Ahn, PhD, Zhen-Huan Hu, MPH, Matt Kalaycio, MD FACP, Richard T. Maziarz, MD, Jorge E. Cortes, MD, Edwin Alyea, MD, Uday R. Popat, MD, Ronald M. Sobecks, MD, Wael Saber, MD MS

Blood (2016) 128 (22): 2256.

https://doi.org/10.1182/blood.V128.22.2256.2256

Published: 2016

Journal Articles

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes: A Center for International Blood and Marrow Transplant Registry (CIBMTR®) Study

Aaron T. Gerds, MD MS, Matt E. Kalaycio, MD, Kwang Woo Ahn, PhD, Zhen-Huan Hu, MPH, Edwin P. Alyea, MD, Uday R. Popat, MD, Ronald M. Sobecks, MD, Wael Saber, MD MS

Blood (2015) 126 (23): 2003.

https://doi.org/10.1182/blood.V126.23.2003.2003

Published: 2015

Journal Articles

A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Brian C Shaffer, MD, Kwang Woo Ahn, PhD, Zhen-Huan Hu, MPH, Uday R. Popat, MD, Matt Kalaycio, MD, Richard T. Maziarz, MD, Edwin Alyea, MD, Ron M Sobecks, MD, Steven Z. Pavletic, MD, Martin S Tallman, MD, Wael Saber, MD MS

Blood (2015) 126 (23): 64.

https://doi.org/10.1182/blood.V126.23.64.64

Published: 2015

NARROW

Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis

Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry

Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Chronic Leukemia Committee

Tyrosine Kinase Inhibitors with or without Donor Lymphocyte Infusion Continue to Provide Long-Term Survival after Relapse of Chronic Myeloid Leukemia Following Hematopoietic Cell Transplantation

Telomere Length and Telomerase Complex Mutations Predict Fatal Treatment Toxicity after Stem Cell Transplantation in Patients with Myelodysplastic Syndrome

Survival Advantage to Allogeneic Transplant in Patients with Myelofibrosis with Intermediate-1 or Higher DIPSS Score

Comparison of Outcomes after Myeloablative Versus Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocyteic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneit HCT: A CIBMTR Report

Optimal Timing of Allogeneic Stem Cell Transplantation (Allo-SCT) for Chronic Myeloid Leukemia (CML) Patients in the Tyrosine Kinase Inhibitor (TKI) Era

Assessment of Human Leukocyte Antigen (HLA) Type on Outcomes of Allogeneic Transplant for Chronic Lymphocytic Leukemia (CLL)

Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes: A Center for International Blood and Marrow Transplant Registry (CIBMTR®) Study

A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only